Claims:

1. A compound or a salt thereof which is (2*S*,3*R*,4*R*)-1-acetyl-2-cyclopropyl-3-methyl-4-((4-methylpyrimidin-2-yl)amino)-1,2,3,4-tetrahydroquinoline-6-carboxylic acid or a salt thereof.

2. A compound or a salt thereof which is (2*S*,3*R*,4*R*)-1-acetyl-2-cyclopropyl-3-methyl-4-((4-methylpyrimidin-2-yl)amino)-1,2,3,4-tetrahydroquinoline-6-carboxamide or a salt thereof.

3. A compound according to claim 1 or claim 2, or a pharmaceutically acceptable salt thereof.

4. A pharmaceutical composition which comprises a compound or a pharmaceutically acceptable salt thereof as defined in claim 3 and one or more pharmaceutically acceptable carriers, diluents or excipients.

5. A combination comprising a compound or a pharmaceutically acceptable salt thereof as defined in claim 3 together with one or more other therapeutically active agents.

6. A compound or a pharmaceutically acceptable salt thereof as defined in claim 3, for use in therapy.

7. A compound or a pharmaceutically acceptable salt thereof as defined in claim 3, for use in the treatment of diseases or conditions for which a bromodomain inhibitor is indicated.

8. A compound or a pharmaceutically acceptable salt thereof for use according to claim 3, wherein the disease or condition is an acute or chronic autoimmune and/or inflammatory condition.

9. A compound or a pharmaceutically acceptable salt thereof for use according to claim 8 wherein the acute or chronic autoimmune and/or inflammatory condition is selected from: rheumatoid arthritis, osteoarthritis, acute gout, psoriasis, systemic lupus erythematosus, multiple sclerosis, inflammatory bowel disease (Crohn's disease and Ulcerative colitis), asthma, chronic obstructive airways disease, pneumonitis, myocarditis, pericarditis, myositis, eczema, dermatitis (including atopic dermatitis), alopecia, vitiligo, bullous skin diseases, nephritis, vasculitis, hypercholesterolemia, atherosclerosis, Alzheimer's disease, depression, Sjögren's syndrome, sialoadenitis, central retinal vein occlusion, branched retinal vein occlusion, Irvine-Gass syndrome (post cataract and post-surgical), retinitis pigmentosa, pars planitis, birdshot retinochoroidopathy, epiretinal membrane, cystic macular edema, parafoveal telengiectasis, tractional maculopathies, vitreomacular traction syndromes, retinal detachment, neuroretinitis, idiopathic macular edema, retinitis, dry eye (keratoconjunctivitis Sicca), vernal keratoconjunctivitis, atopic keratoconjunctivitis, uveitis (such as anterior uveitis, pan uveitis, posterior uveitis, uveitis-associated macular edema), scleritis, diabetic retinopathy, diabetic macula edema, age-related macular dystrophy, hepatitis, pancreatitis, primary biliary cirrhosis, sclerosing cholangitis, Addison's disease, hypophysitis, thyroiditis, type I diabetes, giant cell arteritis, nephritis including lupus nephritis, vasculitis with organ involvement such as glomerulonephritis, vasculitis including giant cell arteritis, Wegener's granulomatosis, Polyarteritis

nodosa, Behcet's disease, Kawasaki disease, Takayasu's Arteritis, pyoderma gangrenosum, vasculitis with organ involvement and acute rejection of transplanted organs.

10. A compound or a pharmaceutically acceptable salt thereof for use according to claim 9 wherein the acute or chronic autoimmune and/or inflammatory condition is psoriasis.

11. A compound or a pharmaceutically acceptable salt thereof for use according to claim 9 wherein the acute or chronic autoimmune and/or inflammatory condition is atopic dermatitis.

12. A compound or a pharmaceutically acceptable salt thereof for use according to claim 9 wherein the acute or chronic autoimmune and/or inflammatory condition is vitiligo.

13. The use of a compound or a pharmaceutically acceptable salt thereof as defined in claim 3, in the manufacture of a medicament for the treatment of an acute or chronic autoimmune and/or inflammatory condition.

14. The use of a compound or a pharmaceutically acceptable salt thereof as defined in claim 13, wherein the acute or chronic autoimmune and/or inflammatory condition is selected from: rheumatoid arthritis, osteoarthritis, acute gout, psoriasis, systemic lupus erythematosus, multiple sclerosis, inflammatory bowel disease (Crohn's disease and Ulcerative colitis), asthma, chronic obstructive airways disease, pneumonitis, myocarditis, pericarditis, myositis, eczema, dermatitis (including atopic dermatitis), alopecia, vitiligo, bullous skin diseases, nephritis, vasculitis, hypercholesterolemia, atherosclerosis, Alzheimer's disease, depression, Sjögren's syndrome, sialoadenitis, central retinal vein occlusion, branched retinal vein occlusion, Irvine-Gass syndrome (post cataract and post-surgical), retinitis pigmentosa, pars planitis, birdshot retinochoroidopathy, epiretinal membrane, cystic macular edema, parafoveal telengiectasis, tractional maculopathies, vitreomacular traction syndromes, retinal detachment, neuroretinitis, idiopathic macular edema, retinitis, dry eye (keratoconjunctivitis Sicca), vernal keratoconjunctivitis, atopic keratoconjunctivitis, uveitis (such as anterior uveitis, pan uveitis, posterior uveitis, uveitis-associated macular edema), scleritis, diabetic retinopathy, diabetic macula edema, age-related macular dystrophy, hepatitis, pancreatitis, primary biliary cirrhosis, sclerosing cholangitis, Addison's disease, hypophysitis, thyroiditis, type I diabetes, giant cell arteritis, nephritis including lupus nephritis, vasculitis with organ involvement such as glomerulonephritis, vasculitis including giant cell arteritis, Wegener's granulomatosis, Polyarteritis nodosa, Behcet's disease, Kawasaki disease, Takayasu's Arteritis, pyoderma gangrenosum, vasculitis with organ involvement and acute rejection of transplanted organs.

15. The use of a compound or a pharmaceutically acceptable salt thereof as defined in claim 14, wherein the acute or chronic autoimmune and/or inflammatory condition is psoriasis.

16. The use of a compound or a pharmaceutically acceptable salt thereof as defined in claim 14, wherein the acute or chronic autoimmune and/or inflammatory condition is atopic dermatitis.

17. The use of a compound or a pharmaceutically acceptable salt thereof as defined in claim 14, wherein the acute or chronic autoimmune and/or inflammatory condition is vitiligo.